home / stock / cyynf / cyynf news
Longeveron has filed proposed terms for a $25 million IPO. The firm is developing a treatment for Alzheimer's Disease and other age-related conditions. LGVN is thinly capitalized and has scant chance of an AD treatment where major pharmas have failed, so I'll pass on the IPO. ...
FDA fails to approve Mesoblast Steroid Refractory Pediatric Graft vs. Host Disease Stem Cell Therapy after FDA advisory board voted 9-1 recommending approval. FDA expresses concerns about Mesoblast MSC manufacturing process in its decision to request another placebo-controlled clinica...
The SARS-CoV2 pandemic has ignited a massive effort across the globe, led by medical researchers and biotech companies, to come up with therapies that can help patients and bring an end to the pandemic. Vaccines, antibodies, immunity and convalescent plasma have all become common medical ter...
On June 14, 2019, I published " The Stem Cell Triple Play: 3 Companies With Great Value Drivers ". Given how out of favor the stem cell sector has been for many years, I was surprised by the massive interest that this article generated. Given this unexpected level of interest and some co...
Regenerative medicine has made steady progress over the last few years, but, with few exceptions, little of that progress has been reflected in appreciating stock prices. From an investor’s mindset, there should be a balanced perspective that weighs the promise of explosive revenue grow...